The aim of this study was to evaluate the species, predisposing factors, antifungal treatment approaches, and clinical outcomes of invasive infections (ICIs) in a tertiary pediatric intensive care unit (PICU). A retrospective study was performed from January 2008 to January 2019 including 102 children with ICIs who were admitted to a university hospital in southeastern Turkey. Positive blood cultures were detected in 43 (42.1%) patients, and positive urine cultures were detected in 59 (57.8%). According to our results, (42.2%) was the most common species for all isolates followed by (17.6%). In our patient population, non- species were dominant (57.8%) in all isolates. The most common facilitating factor in our study was the use of mechanical ventilator support (87.3%). The mortality rate of our patients with ICIs was 13.7%. was found to have the highest mortality rate among all species (30.7%). When we compared patients with and those with non- species in terms of risk factors, we detected a significant difference between the two groups for total parenteral nutrition use (  = 0.027). Fluconazole was the most preferred (58.8%) treatment option in our PICU for ICIs. Our results showed an increased trend in micafungin use in recent years. ICIs are a significant problem due to the high mortality and morbidity rates in critically ill pediatric patients in PICUs. In recent years, an increase in infections caused by non- species has been reported. Multicenter prospective studies are needed to determine the risk factors for ICIs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978178PMC
http://dx.doi.org/10.1055/s-0039-1695061DOI Listing

Publication Analysis

Top Keywords

non- species
12
invasive infections
8
pediatric intensive
8
intensive care
8
care unit
8
cultures detected
8
mortality rate
8
risk factors
8
species
6
icis
6

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!